SCHEMBL1638993

SCHEMBL1638993

CC(C)N1N=C(c2ccc3c(c2)CCN(C2CCC2)CC3)CCC1=O

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 20/20 0.46
CYP2D6 P10635 2/20 0.41
HRH1 P35367 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640089 0.84 PDE4B (0.50) HRH3CYP2D6HRH1
SCHEMBL1639546 0.84 HRH3 (0.44) HRH3CYP2D6HRH1
SCHEMBL1639006 0.83 HRH3 (0.43) HRH3
SCHEMBL1639998 0.82 PDE4B (0.41) HRH3CYP2D6HRH1
SCHEMBL1640636 0.80 PDE4A (0.43) HRH3
SCHEMBL1640654 0.79 PDE3B (0.46) HRH3CYP2D6HRH1
SCHEMBL1638994 0.79 HRH3 (0.40) HRH3
SCHEMBL1640640 0.78 PDE4B (0.42) HRH3CYP2D6HRH1
SCHEMBL1638989 0.78 HRH3 (0.48) HRH3CYP2D6HRH1
SCHEMBL1639554 0.77 ESR1 (0.44) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328586-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS Cephalon, Inc. (US) 2011-06-08 EP claimed
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-04-28 US claimed
WO-2009142732-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-11-26 WO claimed
EP-2328586-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS Cephalon, Inc. (US) 2011-06-08 EP disclosed
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-04-28 US disclosed
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-04-28 US disclosed
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-04-28 US disclosed
WO-2009142732-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-11-26 WO disclosed
WO-2009142732-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands HRH3, HRH4, HRH2 HRH3 1/4885CYP2D6 535/4885HRH1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.